Skip to main content

Table 2 Inclusion and exclusion criteria for NEXT and VENICE

From: Study design: two long-term observational studies of the biosimilar filgrastim Nivestim™ (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia

Inclusion criteria

Exclusion criteria

• Adult patients (NEXT)

• Chronic myeloid leukaemia

• Adult and paediatric patients (VENICE)

• Myelodysplastic syndrome

• Solid tumours or haematological malignancies

• Hypersensitivity to the active substance

• Treated or planned treatment with cytotoxic chemotherapy irrespective of cycle

• Hypersensitivity to one of the excipients of Nivestim™

• Indicated for G-CSF therapy according to the product label for Nivestim™

• Undergoing treatment with G-CSF for ongoing FN (curative) (VENICE only)*

  1. *NEXT includes two patient profiles: curatively and prophylactically treated patients; VENICE includes only patients treated prophylactically. Patients are not excluded if they have congenital neutropenia disorders or have received stem cell transplants.